# Supplementary Figure 3

Supplementary Figure 3: α4 and β7 integrin expression on T_{Reg} and T_{Eff} cells, vedolizumab binding to memory CD4$^+$ T cells and controls for VDZ binding.

(A) Quantitative flow cytometry of α4$^+$β7$^+$ T_{Reg} and T_{Eff} cells in patients with UC and CD compared with healthy controls. n = 17-28 IBD patients or healthy controls as indicated.

(B) Mean fluorescence intensity (MFI) of α4 and β7 integrin on T_{Reg} and T_{Eff} cells in patients with UC and CD an in healthy controls. n = 17-28 IBD patients or healthy controls as indicated.

(C) Quantitative flow cytometry of VDZ$^+$ cells after gating on α4β7$^+$ CD45RO$^+$ T_{Reg} and T_{Eff} cells following incubation with the indicated concentrations of fluorescently labelled vedolizumab. Quantitative data are expressed relative to T_{Eff} cells. n = 25 IBD patients and healthy controls.

(D) Representative fluorescence microscopy of FACS-purified T_{Reg} and T_{Eff} cells stained with isotype controls for β7 antibody (green) and VDZ (red) and counterstained with Hoechst (blue); Scale bar 10 μm. Representative images from 1 out of 6 independent experiments (cells purified from leukocyte cones).

Statistical comparisons were performed using paired t-test (A, C), 2way ANOVA with Sidak's multiple comparison test (B)

Sample donor characteristics are listed in *Supplementary Table S13.*